Abbott Laboratories operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Abbott Laboratories with three other
companies in this sector in UNITED STATES :
Bristol-Myers Squibb Company
sales of $42.52 billion
of which 28%
was Prioritized Brands-Revlimid),
Eli Lilly and Company
of which 29%
was Oncology-Verzenio & Other), and
of which 26%
During the second
quarter of 2021, sales at Abbott Laboratories totalled
an increase of 39.5%
from the $7.33 billion in sales at the company during the second quarter of 2020.
This was the largest same quarter increase in sales since the fourth
quarter of 2017.
During the first two
quarters of 2021, sales totalled $20.68 billion, which is
than through the first two quarters of 2020.
During the year ended December of 2020, sales at
Abbott Laboratories were $34.61 billion.
increase of 8.5%
versus 2019, when the company's sales were $31.90 billion.
This was the fifth consecutive year of sales increases at Abbott Laboratories
(and since 2015, sales have increased a total of 70%).
Sales of Diagnostics Products saw an increase
that was more than double the company's growth rate: sales were up
40.1% in 2020, from
$7.71 billion to $10.81 billion.
Abbott Laboratories also saw significant increases in sales in
Other (up 15.8% to $66.00 million)
Not all segments of Abbott Laboratories experienced an increase in sales in 2020:
sales of Established Pharmaceutical Products fell 4.1% to $4.30 billion.
Abbott Laboratories also experienced decreases in sales in
Medical Devices (down 3.7% to $11.79 billion)